Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
80 hedge funds and large institutions have $56.5M invested in Northwest Biotherapeutics, Inc. Common stock in 2014 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 23 increasing their positions, 15 reducing their positions, and 8 closing their positions.
275% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 8
53% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 15
38% more funds holding
Funds holding: 58 → 80 (+22)
8% more capital invested
Capital invested by funds: $52.5M → $56.5M (+$4.07M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less call options, than puts
Call options by funds: $4.9M | Put options by funds: $5.57M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.02M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$2.28M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.01M |
| 4 |
Goldman Sachs
New York
|
+$1.48M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$9.09M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.32M |
| 3 |
Jane Street
New York
|
-$955K |
| 4 |
SFM
Soros Fund Management
New York
|
-$793K |
| 5 |
U
UBS
Zurich,
Switzerland
|
-$544K |
NWBO Hedge Fund Activity: Q2 2014 in Review
80 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q2 2014, worth a combined $56.5M — up 7.8% from $52.5M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new NWBO positions and 8 closed out — a net gain of 22 holders — while 23 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $5.02M. The largest seller was Franklin Resources, cutting an estimated $9.09M.
- 80 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q2 2014, up from 58 in Q1 2014.
- Funds reported $56.5M of Northwest Biotherapeutics, Inc. Common stock stock for Q2 2014, up 7.8% quarter-over-quarter.
- 30 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q2 2014 and 8 closed out, a net change of +22 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q2 2014 was BlackRock Fund Advisors, an estimated $5.02M added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q2 2014 was Franklin Resources, an estimated $9.09M sold.
Based on aggregated 13F filings for Q2 2014.